Clinical trials: Posterior Uveitis
Behcet Disease
Phase III Study in Refractory Behcet's Disease
The purpose of this pivotal trial is to evaluate subcutaneous (SQ) AIN457 as an adjunctive therapy to reduce the rate of exacerbations of posterior uveitis or panuveitis secondary to Behçet's disease during the 24 weeks of study…
- Trial name
- SHIELD (NCT00995709)
- Testing
- AIN457
- Where
- 49 sites in United States, Egypt and 15 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Uveitis
Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
The purpose of the extension study was to provide patients completing the 28-week core study (NCT01095250) with an opportunity to receive an additional 22 weeks of continuous treatment.
- Trial name
- INSURE (NCT01103024)
- Testing
- AIN457
- Where
- 11 sites in United States, Canada and 3 more
- Sponsor
- Novartis
Noninfectious Posterior Uveitis
Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants
This is a multi-center, randomized, double-masked, controlled study to evaluate the safety and efficacy of fluocinolone acetonide (FA) intravitreal implants for the management of subjects with non-infectious uveitis affecting the…
- Trial name
- NCT00407082
- Testing
- fluocinolone acetonide intravitreal implant, Fluocinolone acetonide 2.1mg
- Where
- United States
- Volunteers
- 278 people
- Sponsor
- Bausch & Lomb Incorporated
Non-infectious Uveitis
Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant vs Standardized Therapy
This is a 3 year,superiority, multicenter, open-label, randomised controlled safety and efficacy study. The aim of this study is to evaluate the effect of an intravitreal fluocinolone acetonide (0.59 mg) implant compared to…
- Trial name
- NCT00468871
- Testing
- fluocinolone acetonide intravitreal implant, corticosteroids and immunosuppressants
- Volunteers
- 140 people
- Sponsor
- Bausch & Lomb Incorporated
Uveitis, Uveitis, Posterior
Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis
This open-label study is designed to evaluate the safety of suprachoroidally administered triamcinolone acetone injectable suspension, CLS-TA, in patients with non-infectious uveitis with and without macular edema.
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate
- Trial name
- AZALEA (NCT03097315)
- Testing
- 4 mg CLS-TA Suprachoriodal Injection
- Where
- 10 sites in United States
- Volunteers
- 38 people
- Sponsor
- Clearside Biomedical, Inc.
Uveitis
38 Week Extension Study to CAIN457C2303
A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet's patients with posterior or panuveitis treated with…
- Trial name
- SHIELD (NCT01093846)
- Testing
- AIN457
- Where
- 25 sites in United States, Egypt and 12 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Intermediate Uveitis, Posterior Uveitis
A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of non-infectious intermediate or posterior uveitis.
- Trial name
- NCT00333814
- Testing
- Dexamethasone
- Where
- 18 sites in United States, Australia and 16 more
- Volunteers
- 229 people
- Sponsor
- Allergan
Retinal Vein Occlusion, Macular Edema
A Long-Term Safety Study of OZURDEX® in Clinical Practice
This study is a multicenter, prospective, observational study to evaluate the long-term safety of OZURDEX® in patients with macular oedema following central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) or…
- Conditions
- Retinal Vein Occlusion, Macular Edema, Uveitis, Posterior
- Trial name
- NCT01539577
- Testing
- dexamethasone 700 μg intravitreal implant
- Where
- 4 sites in France, Germany and 2 more
- Volunteers
- 875 people
- Sponsor
- Allergan
Noninfectious Intermediate, Posterior, or Panuveitis
A Clinical Trial Of Tulisokibart In Participants With Active, Non-Infectious Uveitis (MK-7240-019)
This trial will help researchers learn if tulisokibart, the trial medicine, can treat non-infectious intermediate, posterior, or panuveitis (NIIPPU) so that steroids can be given for a shorter period of time.
- Trial name
- NCT07861074
- Testing
- Tulisokibart, Background prednisone therapy
- Volunteers
- 87 people
- Sponsor
- Merck Sharp & Dohme LLC
Uveitis, Macular Edema
Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis
The study is designed to evaluate the safety and efficacy of triamcinolone acetonide, CLS-TA, in subjects with macular edema following non-infectious uveitis.
- Conditions
- Uveitis, Macular Edema, Uveitis, Posterior, Uveitis, Anterior
- Trial name
- DOGWOOD (NCT02255032)
- Testing
- 4 mg CLS-TA, 0.8 mg CLS-TA
- Where
- 11 sites in United States
- Volunteers
- 22 people
- Sponsor
- Clearside Biomedical, Inc.
Non-infectious Uveitis
Evaluation of EYS606 in Patients With Non-infectious Posterior, Intermediate or Panuveitis
Primary objective: safety and tolerability Secondary objectives: additional indicators of long term safety and indicators of clinical activity Exploratory objectives: to characterize EYS606 biodistribution, immunogenicity and…
- Trial name
- NCT03308045
- Testing
- pEYS606
- Where
- 4 sites in France, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Eyevensys
Noninfectious Uveitis
Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis
The primary objective of this study is to assess the safety and efficacy of voclosporin as therapy in subjects with active noninfectious uveitis involving the intermediate and/or posterior segments of the eye (i.e., anterior +…
- Trial name
- NCT01243983
- Testing
- LX211
- Where
- 52 sites in United States, Austria and 7 more
- Volunteers
- 155 people
- Sponsor
- Lux Biosciences, Inc.
Uveitis, Posterior, Uveitis, Intermediate
Safety &Efficacy of CF101 to Subjects With Uveitis
This is a Phase 2, randomized, double-masked, placebo-controlled study subjects with active, sight-threatening, noninfectious intermediate or posterior uveitis.
- Trial name
- NCT01905124
- Testing
- CF101
- Where
- Israel
- Sponsor
- Can-Fite BioPharma
Non-infectious Uveitis
Safety and Efficacy of AIN457 in Noninfectious Uveitis
This study was performed to evaluate the efficacy and safety of AIN457 for patients with active uveitis that requires systemic immunosuppression.
- Trial name
- NCT00685399
- Testing
- AIN457, AIN 457
- Where
- 23 sites in United States, Germany
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Non-Infectious Uveitis
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
A study to evaluate the safety and efficacy of an FAI insert for the management of subjects with non-infectious uveitis affecting the posterior segment of the eye.
- Trial name
- FAI (NCT01694186)
- Testing
- FAI insert
- Where
- 34 sites in United States, Germany and 4 more
- Volunteers
- 129 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Uveitis
A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis
This is a multicenter, phase 2 trial to explore the efficacy and safety of Izokibep (ABY-035) in treating disease activity in patients with non-Infectious Intermediate, Posterior, Pan-Uveitis with significant disease activity at…
- Trial name
- LINNAEA (NCT04706741)
- Testing
- Izokibep, Prednisone/Prednisolone
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- ACELYRIN Inc.
Macular Edema
A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina
The Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator is used to deliver an implant with medicine to the eye. AbbVie is updating the DEX PS DDS Applicator.
- Trial name
- NCT04976777
- Testing
- Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- AbbVie
Uveitis
Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis
A study comparing the safety and efficacy of adalimumab compared with. placebo in adults with inactive non-infectious intermediate uveitis, posterior uveitis, or panuveitis.
- Trial name
- Visual II (NCT01124838)
- Testing
- Adalimumab, Prednisone
- Volunteers
- 261 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Uveitis, Posterior, Uveitis, Intermediate
A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with clinically quiescent non-infectious uveitis
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Trial name
- LUMINATE (NCT00404742)
- Testing
- LX211
- Where
- 41 sites in United States, Austria and 5 more
- Volunteers
- 232 people
- Sponsor
- Lux Biosciences, Inc.
Non-infectious Intermediate, Posterior and Panuveitis
Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients
The objective of this study is to evaluate the safety and effectiveness of Humira® (Adalimumab) for the treatment of non-infectious intermediate, posterior, or panuveitis patients under a routine treatment practice.
- Trial name
- NCT03339102
- Where
- 17 sites in South Korea
- Volunteers
- 158 people
- Sponsor
- AbbVie